公开(公告)号：US11485742B2

公开(公告)日：2022-11-01

申请号：US17065367

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US11820778B2

公开(公告)日：2023-11-21

申请号：US17818321

申请日：2022-08-08

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

CPC classification number: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US12122761B2

公开(公告)日：2024-10-22

申请号：US18062356

申请日：2022-12-06

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D401/04 ,  A61K45/06

CPC classification number: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US11548865B2

公开(公告)日：2023-01-10

申请号：US17065360

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy Calhoun ,  Xin Chen ,  Kevin Matthew Gardinier ,  Edward Charles Hall ,  Keith Jendza ,  Nancy Labbe-Giguere ,  James Neef ,  Daniel Steven Palacios ,  Ming Qian ,  Michael David Shultz ,  Christopher G. Thomson ,  Kate Yaping Wang ,  Fan Yang

IPC: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.